Alex Chriss, President and CEO, PayPal Paul Hudson, Chief Executive Officer, Sanofi In conversation with: Kristin Stoller, ...

Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multiple national regulatory authorities (NRAs) around the ...

Sanofi today announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). Rippon will continue her role as Country Lead for Sanofi UK & Ireland alongside this ...

Sanofi, who will lead the global diabetes and cardiovascular care business unit in the company's new organisational structure. "The life sciences team at Google can help us improve the patient ...

Through this agreement, Sanofi will transfer its technical expertise and global knowledge in biological technologies ... achieving pharmaceutical security, and effectively contributing to the ...

Sanofi will invest more than €1 billion ($ ... capacity in other parts of the world and boost supply chain security and resiliency. The move ties in with the EU’s position on health ...

Everi Holdings Inc. ("Everi" or the "Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, player loyalty solutions, and bingo, announced ...

The question is what now. Selling out of non-core markets is a tactic Carrefour has employed before. It exited China, which was lossmaking, in 2019 as part of a global consolidation strategy after a ...

The National Institutes of Health-supported initiative aims to collect and share AI-ready data for global scientists to analyze for new ... goals of drawing on unbiased data and protecting the ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.